Mact.Psx

MACT.PSX maintains a relatively strong liquidity position, with a current ratio of 1.84, indicating the company can cover its short-term liabilities with its short-term assets. However, the company's free cash flow of $67.76 million is significantly lower than its operating cash flow of $588.62 million, suggesting that capital expenditures are consuming a large portion of its operating cash. The company's debt-to-equity ratio of 0.28 indicates a conservative capital structure, with equity financing playing a more prominent role than debt.

In terms of profitability, MACT.PSX's return on equity (ROE) of 21.56% and return on assets (ROA) of 11.72% are strong indicators of efficient use of equity and assets to generate profits. These figures are well above the industry median for pharmaceutical companies, which typically range between 10% and 15% for ROE and 5% to 10% for ROA. The company's operating margin, calculated as operating income of $1.28 billion on revenue of $10.36 billion, is 12.36%, which is in line with industry norms.

The company's revenue is primarily concentrated in the United States, with no significant geographic diversification reported in the latest financial disclosures. This concentration may expose the company to regulatory and market risks specific to the U.S. healthcare environment. MACT.PSX operates in a single business segment, focusing on pharmaceutical products, which limits its exposure to multiple revenue streams.

MACT.PSX's growth trajectory appears to be stable, with no significant revenue growth or decline reported in the latest financial period. The company's capital expenditures of -$872.26 million suggest a reduction in investment in physical assets, which could indicate a shift toward cost optimization or a focus on intangible assets. The outlook for the current fiscal year is neutral, with no major changes expected in revenue or profitability.

The company's risk profile is characterized by medium liquidity risk and low dilution risk. The key liquidity flag is the negative net cash position after subtracting total debt, which may require the company to manage its working capital more effectively. The dilution risk is low, as the number of shares outstanding has not changed significantly between basic and diluted shares. No major dilution events have been reported in the latest filings, and the company has not issued new shares recently.

Recent events include the filing of the latest financial statements, which show a stable financial position with no material changes in the company's operations or financial structure. No significant earnings call transcripts or regulatory filings have been disclosed that would indicate a shift in strategy or financial performance.